Metabolic Syndrome in Estonia: Prevalence and Associations with Insulin Resistance

Table 3

Comparison of premorbid¹ and morbid² subgroup in subjects with metabolic syndrome.

Characteristics	Premorbid MS subgroup; 𝑛=51	Morbid MS subgroup; 𝑛=87	𝑃 value
Age (years)	45.86±14.6	57.72±11.3	<0.0001
Waist (cm)	105.3±12.7	109.7±11.1	0.02
Men	106.6±9.9	112.8±8.8	0.008
Women	103.7±15.8	107.5±12.1	0.19
BMI (kg/m²)	32.2±6.1	34.0±25.1	0.03
Men	30.8±4.6	33.2±4.4	0.0495
Women	34.1±7.4	34.6±32.7	0.47
HOMA-IR	2.73±1.8	2.97±2.1	0.50
Men	2.87±1.9	3.14±2.3	0.65
Women	2.54±1.7	2.84±1.8	0.51
Systolic blood pressure (mmHg)	137.1±14.0	143.9±14.2	0.007
Diastolic blood pressure (mmHg)	87.2±8.4	87.7±8.7	0.72
Cholesterol (mmol/L)	6.0±1.4	5.8±1.1	0.85
Triglycerides (mmol/L)	2.03±1.04	1.75±0.77	0.22
HDL-cholesterol (mmol/L) (men)	1.15±0.31	1.22±0.40	0.46
HDL-cholesterol (mmol/L) (women)	1.26±0.26	1.40±0.40	0.14
Fasting glucose (mmol/L)	5.8±0.7	6.3±1.2	0.02
2h glucose during OGTT (mmol/L)	6.5±2.2	7.7±3.1	0.03
Fasting insulin (mU/L)	10.5±6.5	10.4±6.3	0.96
Impaired fasting glucose^¤	6(12)	6(7)	0.4
Impaired glucose tolerance^¤	9(18)	18(21)	0.8
Diabetes^¤	5(10)	28(32)	0.006

Data presented as mean ± SD; ^¤data presented as 𝑛 (%); OGTT: oral glucose tolerance test; Subjects without¹ or with² previously diagnosed and/or treated diabetes, dyslipidaemia, and hypertension.